Compare ZNTL & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZNTL | YARW |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.1M | 154.5M |
| IPO Year | 2020 | 2017 |
| Metric | ZNTL | YARW |
|---|---|---|
| Price | $1.37 | $14.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $7.44 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 1.3M | 170.3K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.03 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.28 | $12.39 |
| 52 Week High | $6.95 | $44.28 |
| Indicator | ZNTL | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 22.22 | 37.85 |
| Support Level | N/A | $12.39 |
| Resistance Level | $1.98 | $20.35 |
| Average True Range (ATR) | 0.18 | 2.79 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 0.72 | 22.69 |
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.